Results 11 to 20 of about 6,428 (208)
Rimonabant for treating tobacco dependence
Vascular Health and Risk Management, 2007 Michael B Steinberg1,2, Jonathan Foulds11University of Medicine and Dentistry of New Jersey–School of Public Health, Tobacco Dependence Program, New Brunswick, NJ, USA; 2University of Medicine and Dentistry of New Jersey–Robert Wood Johnson ...
Michael B Steinberg, Jonathan Foulds
doaj +3 more sources
Vascular Health and Risk Management, 2007 Kirk A Bronander1, Michael J Bloch21Division of General Internal Medicine, 2Divisions of Cardiology and General Internal Medicine, Department of Medicine, University of Nevada School of Medicine, Reno, NV, USAAbstract: The endocannabinoid system (ECS) is
Kirk A Bronander, Michael J Bloch
doaj +2 more sources
(+)-Trans-Cannabidiol Is an Agonist at Human CB<sub>2</sub> Receptors. [PDF]
Pharmacol Res PerspectABSTRACT (−)‐trans‐Cannabidiol ((−)‐CBD) is a principal phytocannabinoid from Cannabis sativa. (−)‐CBD has complex pharmacology but is a relatively weak inhibitor of CB1 and CB2 receptor signaling. Cannabidiol has two chiral centres and thus four stereoisomers.
Burtchaell PB +6 more
europepmc +2 more sources
Rimonabant-induced depression in schizophrenia
Indian Journal of Psychiatry, 2014 Sir, Cannabinoids modulate mood probably through serotonergic neurons in medial prefrontal cortex and cannabinoid receptor (CB1) receptor antagonists may reverse these effects.
Arasappa, Rashmi +6 more
openaire +3 more sources
Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. [PDF]
, 2008 OBJECTIVE Blockade of the CB1 receptor is one of the promising strategies for the treatment of obesity. Although antagonists suppress food intake and reduce body weight, the role of central versus peripheral CB1 activation on weight loss and related ...
Nogueiras, Ruben +13 more
core +3 more sources
Frontiers in Pharmacology, 2023 Introduction: The endocannabinoid system has been implicated in the neurobiology of opioid use disorder. While the CB1 receptor antagonist rimonabant has been shown to block some of the behavioral effects of opioids, studies suggest that the treatment ...
Eduardo A. V. Marinho +12 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Sevoflurane is widely used for maternal anesthesia during pregnancy. Sevoflurane exposure of rats at mid-gestation can cause abnormal development of the central nervous system in their offspring.
Yuxiao Wan +3 more
doaj +1 more source
Depression-like phenotype following chronic CB1 receptor antagonism
Neurobiology of Disease, 2010 Rimonabant was the first clinically marketed cannabinoid (CB)1 receptor antagonist developed to treat obesity. Unfortunately, CB1 receptor antagonism produced adverse psychiatric events in patients.
Chad E. Beyer +11 more
doaj +1 more source
Drugs and Drug Candidates, 2023 The endocannabinoid system is found throughout the CNS and the body where it impacts many important physiological processes. Expectations were high that targeting cannabinoid receptors would prove therapeutically beneficial; pharmaceutical companies ...
Taryn Bosquez-Berger +2 more
doaj +1 more source
Effects of Combined Oleoyl-Estrone and Rimonabant on Overweight Rats
Journal of Pharmacological Sciences, 2007 Oleoyl-estrone (OE) decreases appetite, maintains energy expediture, induces lipolysis (sparing protein), and decreases cholesterolemia and insulin resistance.
Raquel Ferrer-Lorente +3 more
doaj +1 more source